TherapeuticsMD Inc

$ 2.18

-0.46%

21 Apr - close price

  • Market Cap 25,232,100 USD
  • Current Price $ 2.18
  • High / Low $ 2.25 / 2.09
  • Stock P/E N/A
  • Book Value 2.32
  • EPS -0.06
  • Next Earning Report 2026-05-12
  • Dividend Per Share N/A
  • Dividend Yield 0 %
  • Next Dividend Date -
  • ROA -0.04 %
  • ROE -0.02 %
  • 52 Week High 2.95
  • 52 Week Low 0.98

About

TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida.

Analyst Target Price

$5.00

Quarterly Earnings

Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Reported Date 2026-03-272025-11-122025-08-122025-05-082025-03-272024-11-122024-08-122024-05-102024-03-292023-11-142023-08-142023-05-15
Reported EPS 000.050.02190.0219-0.0528-0.0945-0.0766-0.08-0.32-0.24-0.37
Estimated EPS 000None0.040.040.030.03-0.13-0.05-0.070.06
Surprise 000.050-0.0181-0.0928-0.1245-0.10660.05-0.27-0.17-0.43
Surprise Percentage None%None%None%None%-45.25%-232%-415%-355.3333%38.4615%-540%-242.8571%-716.6667%

Next Quarterly Earnings

Mar 2026
Reported Date 2026-05-12
Fiscal Date Ending 2026-03-31
Estimated EPS
Currency USD

Next Dividend Records

Dividend per share (year): -
Dividend Yield -
Next Dividend Date -
Ex-Dividend Date -

Recent News: TXMD

...
TherapeuticsMD Inc. stock outperforms competitors on strong trading day

2026-04-20 17:32:00

TherapeuticsMD Inc. (TXMD) stock rose 5.80% to $2.19 on Monday, defying a general market downturn where the NASDAQ Composite and Dow Jones Industrial Average both saw declines. This gain ended a three-day losing streak for the company. The article highlights the stock's strong performance relative to its competitors on a weaker trading day.

...
TherapeuticsMD Inc. stock outperforms competitors on strong trading day

2026-04-14 17:30:00

TherapeuticsMD Inc. (TXMD) saw its stock advance 2.93% to $2.11, outperforming the overall market on a positive trading day. The NASDAQ Composite Index and Dow Jones Industrial Average also rose. The company's stock closed 28.47% below its 52-week high.

...
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

2026-04-11 00:10:37

TherapeuticsMD, Inc. filed an amended annual report (Form 10-K/A) for the fiscal year ended December 31, 2025, primarily to correct printer errors and update financial schedule details. The company transitioned into a pharmaceutical royalty company in late 2022, deriving revenue from licensing its products like IMVEXXY, BIJUVA, and ANNOVERA, largely through Mayne Pharma. The report also highlights ongoing legal disputes with Mayne Pharma regarding working capital allowances and outlines the company's financial results, showing a reduced net loss for 2025 compared to 2024.

...
Total debt per share of TherapeuticsMD, Inc. – MUN:29TA

2026-04-09 19:11:01

This article provides financial information for TherapeuticsMD, Inc. (MUN:29TA), specifically focusing on its total debt per share. It is presented in a data-centric format from TradingView, indicating market performance on the Munich Stock Exchange. The content is primarily a data label within the TradingView platform, with no further analytical text.

...
EBIT per share of TherapeuticsMD, Inc. – MUN:29TA

2026-04-09 19:09:28

This article displays information regarding the EBIT (Earnings Before Interest and Taxes) per share for TherapeuticsMD, Inc., traded on the Munich Stock Exchange under the symbol 29TA. It appears to be a financial data point from a trading platform, indicating the market is closed and no trades have occurred for this specific data point. The content does not provide detailed financial figures but rather serves as a label for where such data would typically be presented.

...
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market

2026-04-08 17:28:00

TherapeuticsMD Inc. (TXMD) saw its stock rise by 1.49% to $2.05 on Wednesday, despite the broader market's significant gains with the NASDAQ Composite and Dow Jones Industrial Average both increasing by over 2.80%. The company's stock still closed 30.51% below its 52-week high of $2.95, which was reached on January 27th. This movement indicates that while the stock saw a positive day, it underperformed relative to the overall market upswing.

Iscriviti alla nostra newsletter

Email Subscription Form


Resta aggiornato. Ricevi tutti i nuovi articoli e le notizie ogni settimana.
banner startinvesting

Questo si chiuderà in 0 secondi